Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis

Figures & data

Figure 1. Literature search flow diagram.

Table 1. Characteristics of studies included in the meta-analysis.

	Sample size	Intervention	Control	Mean age (years)	Follow-up (weeks)	Lost to follow up (%)
Yang et al.20	54	Ferric citrate	Calcium carbonate	52.5	8	16.7
McIntyre et al.18	63	Fermagate	Placebo	59.1	3	38.1
Chen et al.15	203	SBR759	Sevelamer	58.6	12	14.8
Yokoyama et al.22	192	JTT-751	Placebo	60.1	4	32.8
Yokoyama et al.21	230	JTT-751	Sevelamer	60.8	12	13.1
Wüthrich et al.19	154	PA21	Sevelamer	60.6	6	33.1
Fukagawa et al.17	63	SBR759	Placebo	62.8	4	23.8
Floege et al.16	1059	PA21	Sevelamer	56	24	23.7

Figure 2. (a) Risk of bias graph. (b) Risk of bias summary.

Figure 3. Forest plot of serum phosphorus between iron-based phosphate binders and placebo.

Figure 4. Forest plot of serum iron-related parameters between iron-based phosphate binders and placebo: (a) serum iron; (b) serum transferring saturation; (c) serum total iron binding capacity.

Figure 5. Forest plot of adverse events between iron-based phosphate binders and placebo.

Figure 6. Forest plot of outcomes between iron-based phosphate binders and sevelamer: (a) serum phosphorus; (b) serum calcium; (c) adverse events; (d) all-cause mortality.

Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in hemodialysis patients: Ferric citrate. Nephrol Dial Transplant. 2002;17(2):265–270

 PubMed Web of Science ®Google Scholar

McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ. Iron-magnesium hydroxycarbonate (fermagate): A novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):401–409

 PubMed Web of Science ®Google Scholar

Chen JB, Chiang SS, Chen HC, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011;16(8):743–750

 PubMed Web of Science ®Google Scholar

Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: Results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36(5):478–487

 PubMed Web of Science ®Google Scholar

Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(5):1053--1060

 PubMed Web of Science ®Google Scholar

Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(2):280–289

 PubMed Web of Science ®Google Scholar

Fukagawa M, Kasuga H, Joseph D, et al. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy. Clin Exp Nephrol. 2014;18(1):135–143

 PubMed Web of Science ®Google Scholar

Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638--647

 PubMed Web of Science ®Google Scholar